H3K27M drives OPC stemness and intrathecal therapeutic vulnerability in brainstem glioma organoids.

H3K27M-mutant diffuse midline gliomas maintain OPC stemness through dysregulated ACTIVIN signaling, which can be targeted by intrathecal therapy.

• Why it matters: Effective treatments for brainstem gliomas are limited due to their inaccessibility, blood-brain barrier, and resistance, highlighting the need for models that accurately reflect tumor biology and enable therapy testing.
• What they did: Researchers developed a patient-derived brainstem glioma organoid platform that preserves tumor features and used multi-omics and functional assays to identify OPC stemness mechanisms, then performed intrathecal drug screening with 3-drug therapy (methotrexate, cytarabine, dexamethasone).
• The result: The triple intrathecal therapy (TIT) showed potent effects against DMGs, with organoid-guided personalized treatment inducing sustained responses and CSF proteomic profiling reliably tracking OPC marker reductions, supporting TIT as a promising translational strategy.